Tagged with Manufacturing,

Ecuador Efraim Lakierovich, general manager of Celsius in Ecuador, elaborates on the company’s recent internationalization, the unexpected challenges it has faced in the institutional market and his ambitions to grow the affiliate to the point that it surpasses the size of the Uruguayan headquarters. Could you tell our international readers about…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

Poland Cezary Kilczewski, president and founder of Medicofarma, a Polish CMO, discusses the company’s recent upgrades to double production capacity and the move into R&D operations as well as the dynamics of the possible CMO threat from cheaper nations in the east. He also highlights the strong positing of the company…

Baltics Juris Hmelnickis PhD, Chairman of the Board of JSC Kalceks, explains the story and the evolution of the company in Latvia, its key products in the CNS therapeutic area and how they were able to piggyback on the established footprint of their mother company, JSC Grindeks, to launch products in…

Poland Colm Murphy, general plant manager of Anpharm, a key European production site for the Servier group, highlights major investments in recent years, such as the state-of-the-art QC Lab, and his strategy to increase the plant’s exports. Additionally, he discusses the growing importance of the company’s CDMO activities and the steps…

Poland Andrzej Tarnkowski, founder and owner of Antar, a Polish success story within the orthopaedic field, discusses the company’s successful international expansion into various markets, including Germany, while highlighting the opening of their own production in 2013, offering a huge potential ahead. Finally, he reveals Antar’s strong positioning as the partner…

India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…

Canada Halo Pharma, a US-based one-stop-shop CDMO (Contract Development and Manufacturing Organization), operates out of a site in Mirabel, close to Montreal, that boasts 30 years of experience in developing and manufacturing medicine. Maryse Laliberté, Halo Pharma’s vice-president and general manager, highlights the company’s differentiation factors of quality delivery and flexibility,…

Serbia Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World Bank’s ‘Doing Business’ rankings from 93rd in 2014 to 43rd in 2018. Serbia’s GDP per capita between 2008 and 2016. International comparison of healthcare spending growth and GDP growth between…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…

Poland Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments. Furthermore, he highlights the company’s international strategy and strong manufacturing capabilities, both for their own treatments and in the context…

India A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty generics has led them to success in both the Indian and US markets. When we met in 2011, the company…